Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Eric Lawitz

Showing results (21-30 of 157) with videos related to

Pageof 16
Sort By:
Transplantation|October 31, 2018
Characteristics and Outcomes of Liver Transplantation for Primary Biliary Cholangitis in Young Patients: Analysis of the United Network for Organ Sharing DatabaseAmandeep Singh, Danielle Fritze, Mahsa Mansouri, et al.
Antiviral Research|January 31, 2017
Antiviral response and resistance analysis of treatment-naïve HCV infected patients receiving multiple doses of the NS3 protease inhibitor GS-9256Hongmei Mo, Charlotte Hedskog, Eric Lawitz, et al.
World Journal of Radiology|April 6, 2026
Metabolic profiles and hepatic steatosis assessed by controlled attenuation parameter and elastography during Ramadan fasting in San Antonio, United StatesJazza Jamil, Sabahat Ali, Arif Ahmad, et al.
World Journal of Gastroenterology|May 31, 2019
Ombitasvir/paritaprevir/ritonavir + dasabuvir +/- ribavirin in real world hepatitis C patientsNicole Loo, Eric Lawitz, Naim Alkhouri, et al.
Hepatology (Baltimore, Md.)|April 9, 2014
Patient-reported outcomes in chronic hepatitis C patients with cirrhosis treated with sofosbuvir-containing regimensZobair M Younossi, Maria Stepanova, Fatema Nader, et al.
Antimicrobial Agents and Chemotherapy|July 24, 2013
Characterization of Hepatitis C virus resistance from a multiple-dose clinical trial of the novel NS5A inhibitor GS-5885Kelly A Wong, Angela Worth, Ross Martin, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|April 6, 2026
Baseline Alkaline Phosphatase Impacts Response Rates in Primary Biliary Cholangitis: Exploring Response to Elafibranor in ELATIVECynthia Levy, Christopher L Bowlus, Eric Lawitz, et al.
Contemporary Clinical Trials|April 7, 2023
A phase 2, adaptive randomized, double-blind, placebo-controlled, multicenter, 52-week study of HM15211 in patients with biopsy-confirmed non-alcoholic steatohepatitis - Study design and rationale of HM-TRIA-201 studyManal F Abdelmalek, Ayako Suzuki, Willian Sanchez, et al.
Alimentary Pharmacology & Therapeutics|July 13, 2024
The effect of vitamin E and docosahexaenoic acid ethyl ester on Metabolic Dysfunction-Associated steatotic Liver Disease (MASLD)-A randomised, double-blind, placebo-controlled, parallel-group clinical trial (PUVENAFLD)Naim Alkhouri, Deanna McCarthy, Anne-Cécile V Bayne, et al.
Journal of Hepatology|December 17, 2013
Minimal impact of sofosbuvir and ribavirin on health related quality of life in chronic hepatitis C (CH-C)Zobair M Younossi, Maria Stepanova, Linda Henry, et al.
Pageof 16

Showing results (21-30 of 157) with videos related to

Sort By:
Pageof 16
Transplantation|October 31, 2018
Characteristics and Outcomes of Liver Transplantation for Primary Biliary Cholangitis in Young Patients: Analysis of the United Network for Organ Sharing DatabaseAmandeep Singh, Danielle Fritze, Mahsa Mansouri, et al.
Antiviral Research|January 31, 2017
Antiviral response and resistance analysis of treatment-naïve HCV infected patients receiving multiple doses of the NS3 protease inhibitor GS-9256Hongmei Mo, Charlotte Hedskog, Eric Lawitz, et al.
World Journal of Radiology|April 6, 2026
Metabolic profiles and hepatic steatosis assessed by controlled attenuation parameter and elastography during Ramadan fasting in San Antonio, United StatesJazza Jamil, Sabahat Ali, Arif Ahmad, et al.
World Journal of Gastroenterology|May 31, 2019
Ombitasvir/paritaprevir/ritonavir + dasabuvir +/- ribavirin in real world hepatitis C patientsNicole Loo, Eric Lawitz, Naim Alkhouri, et al.
Hepatology (Baltimore, Md.)|April 9, 2014
Patient-reported outcomes in chronic hepatitis C patients with cirrhosis treated with sofosbuvir-containing regimensZobair M Younossi, Maria Stepanova, Fatema Nader, et al.
Antimicrobial Agents and Chemotherapy|July 24, 2013
Characterization of Hepatitis C virus resistance from a multiple-dose clinical trial of the novel NS5A inhibitor GS-5885Kelly A Wong, Angela Worth, Ross Martin, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|April 6, 2026
Baseline Alkaline Phosphatase Impacts Response Rates in Primary Biliary Cholangitis: Exploring Response to Elafibranor in ELATIVECynthia Levy, Christopher L Bowlus, Eric Lawitz, et al.
Contemporary Clinical Trials|April 7, 2023
A phase 2, adaptive randomized, double-blind, placebo-controlled, multicenter, 52-week study of HM15211 in patients with biopsy-confirmed non-alcoholic steatohepatitis - Study design and rationale of HM-TRIA-201 studyManal F Abdelmalek, Ayako Suzuki, Willian Sanchez, et al.
Alimentary Pharmacology & Therapeutics|July 13, 2024
The effect of vitamin E and docosahexaenoic acid ethyl ester on Metabolic Dysfunction-Associated steatotic Liver Disease (MASLD)-A randomised, double-blind, placebo-controlled, parallel-group clinical trial (PUVENAFLD)Naim Alkhouri, Deanna McCarthy, Anne-Cécile V Bayne, et al.
Journal of Hepatology|December 17, 2013
Minimal impact of sofosbuvir and ribavirin on health related quality of life in chronic hepatitis C (CH-C)Zobair M Younossi, Maria Stepanova, Linda Henry, et al.
Pageof 16